These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 17983937)

  • 1. Use of insulin sensitizers in NASH.
    Khashab M; Chalasani N
    Endocrinol Metab Clin North Am; 2007 Dec; 36(4):1067-87; xi. PubMed ID: 17983937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.
    Idilman R; Mizrak D; Corapcioglu D; Bektas M; Doganay B; Sayki M; Coban S; Erden E; Soykan I; Emral R; Uysal AR; Ozden A
    Aliment Pharmacol Ther; 2008 Jul; 28(2):200-8. PubMed ID: 18445142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues.
    Ratziu V; Caldwell S; Neuschwander-Tetri BA
    Hepatology; 2010 Dec; 52(6):2206-15. PubMed ID: 21105109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic fatty liver disease as a complication of insulin resistance.
    Abdelmalek MF; Diehl AM
    Med Clin North Am; 2007 Nov; 91(6):1125-49, ix. PubMed ID: 17964913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The metabolic syndrome and nonalcoholic fatty liver disease.
    Collantes RS; Ong JP; Younossi ZM
    Panminerva Med; 2006 Mar; 48(1):41-8. PubMed ID: 16633331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance].
    Korenaga M; Kawaguchi K; Korenaga K; Uchida K; Sakaida I
    Nihon Rinsho; 2006 Jun; 64(6):1157-64. PubMed ID: 16768125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving trends in nonalcoholic fatty liver disease.
    Delgado JS
    Eur J Intern Med; 2008 Mar; 19(2):75-82. PubMed ID: 18249301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
    Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain.
    Caballería L; Pera G; Auladell MA; Torán P; Muñoz L; Miranda D; Alumà A; Casas JD; Sánchez C; Gil D; Aubà J; Tibau A; Canut S; Bernad J; Aizpurua MM
    Eur J Gastroenterol Hepatol; 2010 Jan; 22(1):24-32. PubMed ID: 19730384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.
    Nobili V; Manco M; Ciampalini P; Alisi A; Devito R; Bugianesi E; Marcellini M; Marchesini G
    Clin Ther; 2008 Jun; 30(6):1168-76. PubMed ID: 18640473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis.
    Rakoski MO; Singal AG; Rogers MA; Conjeevaram H
    Aliment Pharmacol Ther; 2010 Nov; 32(10):1211-21. PubMed ID: 20955440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatty liver and the metabolic syndrome.
    Neuschwander-Tetri BA
    Curr Opin Gastroenterol; 2007 Mar; 23(2):193-8. PubMed ID: 17268250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.
    Stein LL; Dong MH; Loomba R
    Adv Ther; 2009 Oct; 26(10):893-907. PubMed ID: 19921118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.
    Verna EC; Berk PD
    Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease: a practical approach to evaluation and management.
    Rafiq N; Younossi ZM
    Clin Liver Dis; 2009 May; 13(2):249-66. PubMed ID: 19442917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of action of metformin in nonalcoholic steatohepatitis.
    Mascitelli L; Pezzetta F; Goldstein MR
    Aliment Pharmacol Ther; 2009 Mar; 29(5):602-3; author reply 603-4. PubMed ID: 19183340
    [No Abstract]   [Full Text] [Related]  

  • 17. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors.
    Guaraldi G; Squillace N; Stentarelli C; Orlando G; D'Amico R; Ligabue G; Fiocchi F; Zona S; Loria P; Esposito R; Palella F
    Clin Infect Dis; 2008 Jul; 47(2):250-7. PubMed ID: 18532884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Younossi ZM
    Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of weight loss on nonalcoholic fatty liver disease.
    Rafiq N; Younossi ZM
    Semin Liver Dis; 2008 Nov; 28(4):427-33. PubMed ID: 18956298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome.
    Boppidi H; Daram SR
    Postgrad Med; 2008 Jul; 120(2):E01-7. PubMed ID: 18654060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.